Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis : a multicentre, open-label, partially randomised, phase 2b trial

Tweed, Connor D.Dawson, RodneyBurger, Divan AristoConradie, AlmariCrook, Angela M.Mendel, Carl M.Conradie, FrancescaDiacon, Andreas H.Ntinginya, Nyanda E.Everitt, Daniel E.Haraka, FrederickLi, MengchumVan Niekerk, Christo H.Okwera, AlphonseRassool, Mohammed S.Reither, KlausSebe, Modulakgotla A.Staples, SuzanneVariava, EbrahimSpigelman, Melvin2020-03-102020-03-102019-12Tweed, C.D., Dawson, R., Burger, D.A. et al. 2019, 'Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial', Lancet Respiratory Medicine, vol. 7, no. 12, pp. 1048-1058.2213-2600 (print)2213-2619 (online)10.1016/S2213-2600(19)30366-2http://hdl.handle.net/2263/73699Please read abstract in the article.enArticle is published Open Access.Tuberculosis (TB)Bactericidal activitySafety profilePyrazinamideBedaquiline (BDQ)Pretomanid (PA‐824)MoxifloxacinPulmonary tuberculosisBedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis : a multicentre, open-label, partially randomised, phase 2b trialArticle